Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)


Section Navigation
			
			CDC Home








Tuberculosis Epidemiologic Studies Consortium (TBESC)										Related Pages
										**TBESC-II**
		On This Page
			TBESC-IITBESC-I
		
Holzman SB, Perry A, Saleeb P, Pyan A, Keh C, Salcedo K, Narita M, Ahmed A, Miller TL, Pettit AC, Khurana R, Whipple M, Katz D, Largen A, Krueger A, Shah M. Evaluation of the latent tuberculosis care cascade among public health clinics in the United States. *Clin Infect Dis.* 2022 Apr 1:ciac248. doi: 10.1093/cid/ciac248. Epub ahead of print. PMID: 35363249.
Winglee K, Hill AN, Belknap R, Stout JE, Ayers TL. Variability of interferon-γ release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. *Clin Microbiol Infect.* 2022 Feb 18:S1198-743X(22)00094-5.
Ho CS, Feng PI, Narita M, Stout JE, Chen M, Pascopella L, Garfein R, Reves R, Katz DJ; Tuberculosis Epidemiologic Studies Consortium. Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. *Lancet Infect Dis.* 2022 Jan;22(1):85-96
Largen A, Ayala A, Khurana R, Katz DJ, Venkatappa TK, Brostrom R. Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection. *Int J Tuberc Lung Dis.* 2021 Jul 1;25(7):547-553.
Feng PJ, Wu Y, Ho CS, Chinna L, Whelen AC, Largen A, Brostrom R, Reves R, Belknap R, Cattamanchi A, Banaei N. Impact of T-Cell Xtend on T-SPOT.TB Assay in High-Risk Individuals after Delayed Blood Sample Processing. *J Clin Microbiol.* 2021 Apr 20;59(5):e00120-21. doi: 10.1128/JCM.00120-21. PMID: 33658266; PMCID: PMC8091829
Collins JM, Stout JE, Ayers T, Hill AN, Katz DJ, Ho CS, Blumberg HM, Winglee K; Tuberculosis Epidemiologic Studies Consortium. Prevalence of Latent Tuberculosis Infection among Non-U.S.-Born Persons by Country of Birth – United States, 2012-2017. *Clin Infect Dis.* 2021 Nov 2;73(9):e3468-e3475. 10.1093/cid/ciaa1662. Epub ahead of print. PMID: 33137172.
Ahmed A, Feng PI, Gaensbauer JT, Reves RR, Khurana R, Salcedo K, Punnoose R, Katz DJ for the Tuberculosis Epidemiologic Studies Consortium. Interferon-γ release assays in children <15 years of age. *Pediatrics*. 2020;145:e20191930.
Pettit AC, Stout JE, Belknap R, Benson CA, Séraphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS for the Tuberculosis Epidemiologic Studies Consortium. Optimal testing choice and diagnostic strategies for latent tuberculosis infection among U.S.-born people living with HIV. *Clin Infect Dis.* 2021 Oct 5;73(7):e2278-e2284.
Venkatappa TK, Punnoose R, Katz DJ, Higgins MP, Banaei N, Graviss EA, Belknap RW, Ho CS. Comparing QuantiFERON-TB Gold Plus with other tests to diagnose *Mycobacterium tuberculosis. J Clin Microbiol.* 2019;57:e00985-19.
Stout JE, Wu Y, Ho CS, Pettit AC, Feng PJ, Katz DJ, Ghosh S, Venkatappa T, Luo R for the Tuberculosis Epidemiologic Studies Consortium. Evaluating latent tuberculosis infection diagnostics using latent class analysis. *Thorax*. 2018;73:1062-1070.
Stout JE, Belknap R, Wu YJ, Ho CS. Paradox of serial interferon-gamma release assays: variability width more important than specificity size. *Int J Tuberc Lung Dis*. 2018;22:518-523.**TBESC-I**
Reichler MR, Khan A, Yuan Y, Chen B, McAuley J, Mangura BT, Sterling TR and the Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Duration of Exposure Among Close Contacts of Infectious Tuberculosis Patients and Risk of Latent Tuberculosis Infection. Clin Infect Dis 2019
Sharling L, Marks SM, Goodman M, Chorba T, Mase S. Rifampin-resistant tuberculosis in the United States, 1998-2014. Clin Infect Dis 2019 Jun 22. pii: ciz491. doi: 10.1093/cid/ciz491.
Reichler MR, Khan A, Sterling TR, Zhao H, Chen B, Yuan Y, Moran J, McAuley J, Mangura B; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk factors for tuberculosis and effect of preventive therapy among close contacts of persons with infectious tuberculosis. Clin Infect Dis. 2019 May 24. pii: ciz438. doi: 10.1093/cid/ciz438.
Marks SM, Katz DJ, Davidow AL, Pagaoa MA, Teeter LD, Graviss EA. The impact of HIV infection on TB disparities among U.S.-born black and white tuberculosis patients in the United States. J Public Health Manag Pract.  2019 Feb 14. doi: 10.1097/PHH.0000000000000949.
Beavers SF, Pascopella L, Davidow AL, Mangan JM, Hirsch-Moverman YR, Golub JE, Blumberg HM, Webb RM, Royce RA, Buskin SE, Leonard MK, Weinfurter PC, Belknap RW, Hughes SE, Warkentin JV, Welbel SF, Miller TL, Kundipati SR, Lauzardo M, Barry PM, Katz DJ, Garrett DO, Graviss EA, Flood JM; Tuberculosis Epidemiologic Studies Consortium. Tuberculosis Mortality in the United States: Epidemiology and Prevention Opportunities. Ann Am Thorac Soc. 2018;15:683-92.
Reichler MR, Khan A, Sterling TR, Zhao H, Moran J, McAuley J, Bessler P, Mangura B; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis. Infect Dis 2018 May 15.
doi: 10.1093/infdis/jiy265.
Lambert LA, Katz D, Feng PJ, Djojonegoro BM, Fair E, Jasuja S, Marantz S, Horsburgh CR Jr, Ho C. Impact of choice of test for latent tuberculosis infection on treatment acceptance and completion. Microbiology Insights. Microbiol Insights. 2018 Nov 27; 11:1178636118811311. doi: 10.1177/1178636118811311. eCollection 2018
Teeter LD, Kammerer JS, Ghosh S, Nguyen DTM, Vempaty P, Tapia J, Miramontes R, Cronin WA, Graviss EA; Tuberculosis Epidemiologic Studies Consortium. Evaluation of 24-locus MIRU-VNTR genotyping in Mycobacterium tuberculosis cluster investigations in four jurisdictions in the United States, 2006–2010. Tuberculosis 2017;106:9-15.  doi: 10.1016/j.tube.2017.05.003.
Royce RA, Colson PW, Woodsong C, Swinson-Evans T, Walton W, Maiuri A, DeLuca N; Tuberculosis Epidemiologic Studies Consortium (TBESC). Tuberculosis knowledge, awareness, and stigma among African-Americans in three southeastern counties in the USA: a qualitative study of community perspectives.  J Racial Ethn Health Disparities 2017;4:47-58.
Agarwal S, Nguyen DT, Lew JD, Teeter LD, Yamal JM, Restrepo BL, Brown EL, Dorman SE, Graviss EA. Comparing TSPOT assay results between an Elispot reader and manual counts. Tuberculosis 2016;101S:S92-S98.
Agarwal S, Nguyen DT, Lew JD, Teeter LD, Yamal JM, Restrepo BL, Brown EL, Dorman SE, Graviss EA. Differential positive TSPOT assay responses to ESAT-6 and CFP-10 in health care workers.  Tuberculosis 2016;101S:S83-S91.
Marks SM, Hirsch-Moverman Y, Salcedo K, Graviss EA, Oh P, Seaworth B, Flood J, Armstrong L, TB Epidemiologic Studies Consortium. Characteristics and costs associated with hospitalization for multidrug-resistant tuberculosis care in the United States, 2005-2007.  Int J Tuberc Lung Dis 2016;20:435-41.
Teeter LD, Vempaty P, Nguyen DT, Tapia J, Sharnprapai S, Ghosh S, Kammerer JS, Miramontes R, Cronin WA, Graviss EA, Tuberculosis Epidemiologic Studies Consortium. Validation of genotype cluster investigations for Mycobacterium tuberculosis: application results for 44 clusters from four heterogeneous United States jurisdictions.  BMC Infect Dis 2016;16:594.
Collins JM, Reves RR, Belknap RW. High rates of tuberculosis and opportunities for prevention among international students in the U.S. Ann Am Thorac Soc 2016;13:522-8.
Aiona K, Lowenthal P, Painter JA, Reves R, Flood J, Parker M, Fu Y, Wall K, Walter ND. Transnational record linkage for tuberculosis surveillance and program evaluation. Public Health Rep 2015;130:475-84.
Howley MM, Painter JA, Katz DJ, Graviss EA, Reves R, Beavers SF, Garrett DO; Tuberculosis Epidemiologic Studies Consortium. Evaluation of QuantiFERON-TB gold in-tube and tuberculin skin tests among immigrant children being screened for latent tuberculosis infection. Pediatr Infect Dis J 2015;34:35-9.
Miller TL, Wilson FA, Pang JW, Beavers S, Hoger S, Sharnprapai S, Pagaoa M, Katz DJ, Weis SE. Mortality hazard and survival after tuberculosis treatment. Am J Public Health 2015;105:930-7.
Hirsch-Moverman Y, Cronin WA, Chen B, Moran JA, Munk E, Reichler MR; Tuberculosis Epidemiological Studies Consortium.  HIV counseling and testing in tuberculosis contact investigations in the United States and Canada.  Int J Tuberc Lung Dis 2015;19:943–53.
Pagaoa MA, Royce RA, Chen MP, Golub JE, Davidow AL, Hirsch-Moverman Y, Marks SM, Teeter LD, Thickstun PM, Katz DJ; Tuberculosis Epidemiologic Studies Consortium. Risk factors for transmission of tuberculosis among United States-born African Americans and whites.  Int J Tuberc Lung Dis 2015;19:1485-92.
Howley MM, Rouse CD, Katz DJ, Colson PW, Hirsch-Moverman Y, Royce RA; Tuberculosis Epidemiologic Studies Consortium. Knowledge and attitudes about tuberculosis among U.S.-born blacks and whites with tuberculosis. J Immigr Minor Health 2015;17:1487-95.
Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, Blumberg HM, Venkatappa TK, Horsburgh CR, Colson PW; Tuberculosis Epidemiologic Studies Consortium (TBESC). Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis 2015;19:31-8.
Davidow AL, Katz D, Ghosh S, Blumberg H, Tamhane A, Sevilla A, Reves R; Tuberculosis Epidemiologic Studies Consortium. Preventing infectious pulmonary tuberculosis among foreign-born residents of the United States. Am J Public Health 2015;105:e81-8.
Walter ND, Painter J, Parker M, Lowenthal P, Flood J, Fu Y, Asis R, Reves R; Tuberculosis Epidemiologic Studies Consortium. Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med 2014;189:88-95.
Miller TL, Carlson EK, Lackan, NA. Playing to our Strengths: An Academic/Health Department Collaboration to Facilitate Public Protections Against Tuberculosis. Frontiers in Public Health Services and Systems Research 2014; 3:(2),Article 3.
Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, Wang Y, Cronin W, Hirsch-Moverman Y, Teeter LD, Parker M, Garrett DO, Daley CL; Tuberculosis Epidemiologic Studies Consortium. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States.  Am J Respir Crit Care Med 2014;189:77-87.
Fiske CT, Yan FX, Hirsch-Moverman Y, Sterling TR, Reichler MR; Tuberculosis Epidemiologic Studies Consortium. Risk factors for treatment default in close contacts with latent tuberculous infection. Int J Tuberc Lung Dis. 2014;18:421-7.
Colson PW, Couzens GL, Royce RA, Kline T, Chavez-Lindell T, Welbel S, Pang J, Davidow A, Hirsch-Moverman Y; Tuberculosis Epidemiologic Studies Consortium (TBESC). Examining the impact of patient characteristics and symptomatology on knowledge, attitudes, and beliefs among foreign-born tuberculosis cases in the US and Canada.  J Immigr Minor Health 2014;16:125-35.
Pang J, Teeter LD, Katz DJ, Davidow AL, Miranda W, Wall K, Ghosh S, Stein-Hart T, Restrepo BI, Reves R, Graviss EA; Tuberculosis Epidemiologic Studies Consortium. Epidemiology of tuberculosis in young children in the United States. Pediatrics 2014;133:e494-504.
Hoger S, Lykens K, Beavers SF, Katz D, Miller TL. Longevity loss among cured tuberculosis patients and the potential value of prevention.  Int J Tuberc Lung Dis 2014;18:1347-52
Pascopella L, Franks J, Marks SM, Salcedo K, Schmitz K, Colson PW, Hirsch-Moverman Y, Flood J, Sayles J. Opportunities for tuberculosis diagnosis and prevention among persons living with HIV: a cross-sectional study of policies and practices at four large Ryan White Program-Funded HIV clinics.  PLoS One 2014;9:e101313.
Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, Armitige L, Revuelta M, Sheeran K, TB Epidemiologic Studies Consortium.  Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis. 2014 May;20(5):812-21.
Moonan PK, Teeter LD, Salcedo K, Ghosh S, Ahuja SD, Flood J, Graviss EA. Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study. Lancet Infect Dis 2013;13:777-84.
Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR; Tuberculosis Epidemiologic Studies Consortium. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.  J Infect 2013;67:424-32.
Colson PW, Hirsch-Moverman Y, Bethel J, Vempaty P, Salcedo K, Wall K, Miranda W, Collins S, Horsburgh CR; Tuberculosis Epidemiologic Studies Consortium. Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada. Int J Tuberc Lung Dis 2013;17:473-9.
Painter JA, Graviss EA, Hai HH, Nhung DT, Nga TT, Ha NP, Wall K, Loan le TH, Parker M, Manangan L, O’Brien R, Maloney SA, Hoekstra RM, Reves R. Tuberculosis screening by tuberculosis skin test or QuantiFERON-TB Gold In-Tube Assay among an immigrant population with a high prevalence of tuberculosis and BCG vaccination.  PLoS One 2013;8:e82727.
Marks SM, Cronin W, Venkatappa T, Maltas G, Chon S, Sharnprapai S, Gaeddert M, Tapia J, Dorman SE, Etkind S, Crosby C, Blumberg HM, Bernardo J. The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States.  Clin Infect Dis 2013;57:532-42.
Hirsch-Moverman Y, Wall K, Weinfurter P, Munk E, Moran JA, Maiuris A, Khan A, DeLuca N; TB Epidemiologic Studies Consortium. Acceptability of interferon-gamma release assays among healthcare workers who receive routine employee tuberculosis testing. Int J Occup Environ Health 2013;19:319-24.
Lurie S, Weis S, Munguia G. Roles of Hispanic service organizations in tuberculosis education and health promotion. Chapter 12 in: Building Community Capacity: Minority and Immigrant Populations. R. Caron and J. Merrick, editors. N.Y.: Nova Science Publishers, 2012.
Weinfurter P, Blumberg HM, Goldbaum G, Royce R, Pang J, Tapia J, Bethel J, Mazurek GH, Toney S, Albalak R; Tuberculosis Epidemiological Studies Consortium. Predictors of discordant tuberculin skin test and QuantiFERON®-TB Gold In-Tube results in various high-risk groups.  Int J Tuberc Lung Dis 2011;15:1056-61.
Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, Weinfurter P; Tuberculosis Epidemiologic Studies Consortium. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137:401-9.
Phillips VL, Teweldemedhin B, Ahmedov S, Cobb J, McNabb SJ. Evaluation of program performance and expenditures in a report of performance measures (RPM) via a case study of two Florida county tuberculosis programs.  Eval Program Plann 2010;33:373-8.
Davidow AL, Katz D, Reves R, Bethel J, Ngong L; Tuberculosis Epidemiologic Studies Consortium. The challenge of multisite epidemiologic studies in diverse populations: design and implementation of a 22-site study of tuberculosis in foreign-born people. Public Health Rep 2009;124:391-9.
Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, Albalak R, Blumberg HM. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis. 2009;9:9-15.
Lobato MN, Sun SJ, Moonan PK, Weis SE, Saiman L, Reichard AA, Feja K; Zero Tolerance for Pediatric TB Study Group. Underuse of effective measures to prevent and manage pediatric tuberculosis in the United States.  Arch Pediatr Adolesc Med. 2008;162:426-31.
Katz D, Albalak R, Wing JS, Combs V; Tuberculosis Epidemiologic Studies Consortium. Setting the agenda: a new model for collaborative tuberculosis epidemiologic research.  Tuberculosis 2007;87:1-6.
Li J, Marks SM, Driver CR, Diaz FA, Castro AF 3rd, de Regner AF, Gibson AE, Dokubo-Okereke K, Munsiff SS; Tuberculosis Epidemiologic Studies Consortium. Human immunodeficiency virus counseling, testing, and referral of close contacts to patients with pulmonary tuberculosis: feasibility and costs. J Public Health Manag Pract. 2007;13:252-62.
Hance FL, Steingart KR, Hahn CG, Pascopella L, Nolan CM. Field assessment of a model tuberculosis outbreak response plan for low-incidence areas. BMC Public Health 2007;7:307.
Cook VJ, Sun SJ, Tapia J, Muth SQ, Arguello DF, Lewis BL, Rothenberg RB, McElroy PD. Transmission network analysis in tuberculosis contact investigations. J Infect Dis 2007;196:1517-27.
Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR, Tuberculosis Epidemiologic Studies Consortium. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006;173:927-31.
Miller TL, Hilsenrath P, Lykens K, McNabb SJ, Moonan PK, Weis SE. Using cost and health impacts to prioritize the targeted testing of tuberculosis in the United States. Ann Epidemiol 2006;16:305-12.
McNabb SJ, Surdo AM, Redmond A, Cobb J, Wiley J, Chakrabarti S, Duncan H, Qualls N, Moore M. Applying a new conceptual framework to evaluate tuberculosis surveillance and action performance and measure the costs, Hillsborough County, Florida, 2002.  Ann Epidemiol 2004;14:640-5.
							
					
							Last Reviewed:  February 27, 2023						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue